In-vivo and human evidence for potential efficacy of therapeutic polyclonal RSV neutralizing antibodies for palivizumab-resistant RSV infections.

[1]  B. Alexander,et al.  Oral and Inhaled Ribavirin Treatment for Respiratory Syncytial Virus Infection in Lung Transplant Recipients , 2020, Transplantation.

[2]  Tamekia Jones,et al.  Respiratory Syncytial Virus Disease Severity is Associated with Distinct CD8+ T Cell Profiles. , 2020, American journal of respiratory and critical care medicine.

[3]  C. Steiner,et al.  Hospitalizations associated with respiratory syncytial virus (RSV) and influenza in children, including children diagnosed with asthma. , 2019, Epidemiology.

[4]  N. Akseer,et al.  Risk stratification of immunocompromised children, including pediatric transplant recipients at risk of severe respiratory syncytial virus disease , 2019, Pediatric transplantation.

[5]  N. Patel,et al.  Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge. , 2018, Vaccine.

[6]  J. Wu,et al.  Comparison of antiviral resistance across acute and chronic viral infections , 2018, Antiviral research.

[7]  R. Wasserman,et al.  RI-002, an intravenous immunoglobulin containing high titer neutralizing antibody to RSV and other respiratory viruses for use in primary immunodeficiency disease and other immune compromised populations , 2017, Expert review of clinical immunology.

[8]  E. Walsh,et al.  Compassionate use experience with high‐titer respiratory syncytical virus (RSV) immunoglobulin in RSV‐infected immunocompromised persons , 2017, Transplant infectious disease : an official journal of the Transplantation Society.

[9]  R. Kobayashi,et al.  Efficacy, Safety, and Pharmacokinetics of a New 10 % Liquid Intravenous Immunoglobulin Containing High Titer Neutralizing Antibody to RSV and Other Respiratory Viruses in Subjects with Primary Immunodeficiency Disease , 2016, Journal of Clinical Immunology.

[10]  F. Dignan,et al.  BCSH/BSBMT/UK clinical virology network guideline: diagnosis and management of common respiratory viral infections in patients undergoing treatment for haematological malignancies or stem cell transplantation , 2016, British journal of haematology.

[11]  A. Falsey,et al.  Treatment with novel RSV Ig RI-002 controls viral replication and reduces pulmonary damage in immunocompromised Sigmodon hispidus , 2015, Bone Marrow Transplantation.

[12]  P. Szilagyi,et al.  Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis , 2015, Journal of Clinical Virology.

[13]  J. Devincenzo,et al.  Respiratory syncytial virus (RSV) and its propensity for causing bronchiolitis , 2014, The Journal of pathology.

[14]  Rob Lambkin-Williams,et al.  Oral GS-5806 activity in a respiratory syncytial virus challenge study. , 2014, The New England journal of medicine.

[15]  Eneida A. Mendonça,et al.  Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection , 2014, Pediatrics.

[16]  Ruchi M. Newman,et al.  Within-Host Whole-Genome Deep Sequencing and Diversity Analysis of Human Respiratory Syncytial Virus Infection Reveals Dynamics of Genomic Diversity in the Absence and Presence of Immune Pressure , 2014, Journal of Virology.

[17]  H. Einsele,et al.  Fourth European Conference on Infections in Leukaemia (ECIL-4): Guidelines for Diagnosis and Treatment of Human Respiratory Syncytial Virus, Parainfluenza Virus, Metapneumovirus, Rhinovirus, and Coronavirus , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  N. Patel,et al.  Natural polymorphisms and resistance-associated mutations in the fusion protein of respiratory syncytial virus (RSV): effects on RSV susceptibility to palivizumab. , 2012, The Journal of infectious diseases.

[19]  P. Piedra,et al.  Role of Neutralizing Antibodies in Adults With Community-Acquired Pneumonia by Respiratory Syncytial Virus , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[20]  M. Bergeron,et al.  Molecular Evolution of Respiratory Syncytial Virus Fusion Gene, Canada, 2006–2010 , 2012, Emerging infectious diseases.

[21]  C. Renaud,et al.  Changing epidemiology of respiratory viral infections in hematopoietic cell transplant recipients and solid organ transplant recipients , 2011, Current opinion in infectious diseases.

[22]  N. Patel,et al.  Analysis of respiratory syncytial virus preclinical and clinical variants resistant to neutralization by monoclonal antibodies palivizumab and/or motavizumab. , 2011, The Journal of infectious diseases.

[23]  G. Somes,et al.  Risk Factors for Severe Respiratory Syncytial Virus Disease in Children With Cancer: The Importance of Lymphopenia and Young Age , 2008, Pediatrics.

[24]  Anami R Patel,et al.  Comparison of a Real-Time Reverse Transcriptase PCR Assay and a Culture Technique for Quantitative Assessment of Viral Load in Children Naturally Infected with Respiratory Syncytial Virus , 2005, Journal of Clinical Microbiology.

[25]  J. Kahn,et al.  Surveillance of clinical isolates of respiratory syncytial virus for palivizumab (Synagis)-resistant mutants. , 2004, The Journal of infectious diseases.

[26]  J. Suzich,et al.  Quantitative effects of palivizumab and donor-derived T cells on chronic respiratory syncytial virus infection, lung disease, and fusion glycoprotein amino acid sequences in a patient before and after bone marrow transplantation. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[27]  E. Walsh,et al.  Humoral and mucosal immunity in protection from natural respiratory syncytial virus infection in adults. , 2004, The Journal of infectious diseases.

[28]  S. Crawford,et al.  Phase 1 evaluation of the respiratory syncytial virus-specific monoclonal antibody palivizumab in recipients of hematopoietic stem cell transplants. , 2001, The Journal of infectious diseases.

[29]  J. Devincenzo,et al.  Respiratory Syncytial Virus Infections in Hematopoietic Stem Cell Transplant Recipients and other Severely Immunocompromised Patients , 2000 .

[30]  O. Ramilo,et al.  Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein. , 1998, The Journal of infectious diseases.

[31]  R. Soiffer,et al.  Immunotherapy of respiratory syncytial virus pneumonia following bone marrow transplantation. , 1996, Bone marrow transplantation.

[32]  E. Walsh,et al.  Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin. , 1994, The Journal of infectious diseases.

[33]  A. Randolph,et al.  Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children. , 2004, The Cochrane database of systematic reviews.

[34]  R. Hirsch,et al.  Respiratory syncytial virus immune globulin treatment of lower respiratory tract infection in pediatric patients undergoing bone marrow transplantation – a compassionate use experience , 2000, Bone Marrow Transplantation.

[35]  O. Ramilo,et al.  Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretions. , 2000, The Pediatric infectious disease journal.

[36]  P. Piedra,et al.  Enhanced pulmonary pathology associated with the use of formalin-inactivated respiratory syncytial virus vaccine in cotton rats is not a unique viral phenomenon. , 1993, Vaccine.